Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study
- 26 July 2013
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (8) , 1253-1261
Abstract
Objectives: To assess the distribution of antihyperglycemic treatments according to age and renal function and its relationship with cardiovascular disease in type 2 diabetes mellitus ( T2DM ). Design: Cross‐sectional analysis. Setting: Nineteen hospital‐based diabetes mellitus clinics in 2007 and 2008. Participants: Fifteen thousand seven hundred thirty‐three individuals with T2DM from the Renal Insufficiency and Cardiovascular Events ( RIACE ) Italian Multicenter Study. Measurements: Current antihyperglycemic treatments were recorded. Estimated glomerular filtration rate ( eGFR ) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Albuminuria was measured using immunonephelometry or immunoturbidimetry. Prevalence of major acute cardiovascular events was calculated according to age quartiles, treatments, and categories of eGFR (1 = ≥90; 2 = 60–89; 3 = 30–59; and 4 = 2 ). Results: Across age quartiles, eGFR declined progressively at a time‐linear rate, with an acceleration in older adults, whereas albuminuria increased; age and eGFR were associated with cardiovascular events independently of other confounders. With increasing age, percentage of participants using lifestyle treatments for their T2DM and taking metformin or glitazones fell; percentage taking sulphonylureas and repaglinide rose, and percentage taking insulin remained stable. In eGFR categories 3 and 4, use of metformin was 41.4% and 14.5%, respectively, and that of sulphonylureas was 34.2% and 18.1%, respectively. Inappropriate prescription of these agents, especially sulphonylureas, increased with age. Metformin was independently associated with lower prevalence of cardiovascular disease for any age quartile and eGFR category than all other treatments. Conclusion: In real‐life conditions, use of agents that are not recommended in elderly adults with diabetes mellitus with moderate to severe renal impairment is frequent, but metformin is associated with lower cardiovascular event rates even in these individuals.Keywords
Funding Information
- Research Foundation of the Italian Society of Diabetology
- Diabetes, Endocrinology and Metabolism Foundation
- Eli-Lilly Italia
- Takeda
- Chiesi Farmaceutici
- Boehringer-Ingelheim
This publication has 40 references indexed in Scilit:
- Comparative effectiveness of incident oral antidiabetic drugs on kidney functionKidney International, 2012
- Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 DiabetesNew England Journal of Medicine, 2011
- Association Between Glycemic Control and Adverse Outcomes in People With Diabetes Mellitus and Chronic Kidney DiseaseArchives of internal medicine (1960), 2011
- Clinical Manifestation and Natural History of Diabetic Nephropathy2011
- Epidemiology of Diabetic Nephropathy2011
- Kidney function and risk triage in adults: threshold values and hierarchical importanceKidney International, 2011
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Management of Glycemia in Patients With Diabetes Mellitus and CKDAmerican Journal of Kidney Diseases, 2007